key: cord-0897646-u8kf7165
authors: Rodríguez-Serrano, Diego A.; Roy-Vallejo, Emilia; Zurita Cruz, Nelly D.; Martín Ramírez, Alexandra; Rodríguez-García, Sebastián C.; Arevalillo-Fernández, Nuria; Galván-Román, José María; Fontán García-Rodrigo, Leticia; Vega-Piris, Lorena; Chicot Llano, Marta; Arribas Méndez, David; González de Marcos, Begoña; Hernando Santos, Julia; Sánchez Azofra, Ana; Ávalos Pérez-Urria, Elena; Rodriguez-Cortes, Pablo; Esparcia, Laura; Marcos-Jimenez, Ana; Sánchez-Alonso, Santiago; Llorente, Irene; Soriano, Joan; Suárez Fernández, Carmen; García-Vicuña, Rosario; Ancochea, Julio; Sanz, Jesús; Muñoz-Calleja, Cecilia; de la Cámara, Rafael; Canabal Berlanga, Alfonso; González-Álvaro, Isidoro; Cardeñoso, Laura
title: Detection of SARS-CoV-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients
date: 2021-06-23
journal: Sci Rep
DOI: 10.1038/s41598-021-92497-1
sha: fa494b0e43550e61b51dd74f9119a6cf5d8dd025
doc_id: 897646
cord_uid: u8kf7165

COVID-19 has overloaded national health services worldwide. Thus, early identification of patients at risk of poor outcomes is critical. Our objective was to analyse SARS-CoV-2 RNA detection in serum as a severity biomarker in COVID-19. Retrospective observational study including 193 patients admitted for COVID-19. Detection of SARS-CoV-2 RNA in serum (viremia) was performed with samples collected at 48–72 h of admission by two techniques from Roche and Thermo Fischer Scientific (TFS). Main outcome variables were mortality and need for ICU admission during hospitalization for COVID-19. Viremia was detected in 50–60% of patients depending on technique. The correlation of Ct in serum between both techniques was good (intraclass correlation coefficient: 0.612; p < 0.001). Patients with viremia were older (p = 0.006), had poorer baseline oxygenation (PaO(2)/FiO(2); p < 0.001), more severe lymphopenia (p < 0.001) and higher LDH (p < 0.001), IL-6 (p = 0.021), C-reactive protein (CRP; p = 0.022) and procalcitonin (p = 0.002) serum levels. We defined "relevant viremia" when detection Ct was < 34 with Roche and < 31 for TFS. These thresholds had 95% sensitivity and 35% specificity. Relevant viremia predicted death during hospitalization (OR 9.2 [3.8–22.6] for Roche, OR 10.3 [3.6–29.3] for TFS; p < 0.001). Cox regression models, adjusted by age, sex and Charlson index, identified increased LDH serum levels and relevant viremia (HR = 9.87 [4.13–23.57] for TFS viremia and HR = 7.09 [3.3–14.82] for Roche viremia) as the best markers to predict mortality. Viremia assessment at admission is the most useful biomarker for predicting mortality in COVID-19 patients. Viremia is highly reproducible with two different techniques (TFS and Roche), has a good consistency with other severity biomarkers for COVID-19 and better predictive accuracy.

Demographic and clinical characteristics of the study population. One hundred and ninety-three patients were included; their main demographic and baseline clinical characteristics and laboratory findings are shown in Table 1 and S1 Table. Depending on the technique, viremia was detected in 95 (48%; Roche) and 117 (59%; TFS) patients; the correlation between Ct (Cycle threshold) in serum obtained with both techniques was very good (r = 0.738 [0.667-0.795], p < 0.001), and detection by TFS was more sensitive than by Roche (S1A Figure) . The agreement to detect viremia was 75.5% and the intraclass correlation coefficient was 0.612 (p < 0.001). Conversely, the correlation of Ct between nasopharyngeal and throat swab (NPTS) and serum samples was weak either with TFS or Roche techniques (S1B,C Figure, respectively).

Patients with detectable viremia were older (p = 0.006), with worse baseline arterial oxygen tension/fraction of inspired oxygen ratio (PaO 2 /FiO 2 ; p < 0.001), lower lymphocyte count (p < 0.001) and higher LDH (p < 0.001), IL-6 (p = 0.021), C-reactive protein (CRP; p = 0.022) and procalcitonin (p = 0.002) serum levels compared to patients without detectable viremia. In addition, they were more frequently treated with glucocorticoids (p = 0.016), either oral or bolus (p = 0.015), and with tocilizumab (p = 0.001) ( Table 1 and S1 Table) .

There were no significant differences in symptom duration at the time of sample collection between patients with and without viremia (9 days [95%CI 4-13] and 8 [6] [7] [8] [9] [10] [11] Prevalence of SARS-CoV-2 viremia is higher in patients requiring ICU admission. In order to evaluate the relationship between COVID-19 severity and viremia we first studied the relative frequency of viremia in patients who required ICU admission and those who did not. As shown in Fig. 1 , viremia was significantly more frequent for both techniques in patients requiring ICU (p < 0.001 for Roche and p = 0.002 for TFS). Although TFS was more sensitive to detect viremia, it seemed to be less specific to predict the need for ICU (OR 2.47 [95% CI 1.37-4.47], p = 0.003 for TFS vs 3.04 [1.71-5.44 ] p < 0.001 for Roche).

Additionally, we performed a multivariable logistic regression in order to determine whether viremia can help predicting ICU admission compared to other variables. The best model to predict the need for ICU admission included the following variables: COPD, total lymphocyte count and PaO 2 /FiO 2 at admission ( Table 2) . When we forced viremia into this model, it did not reach statistical significance either when it was assessed by Roche or by TFS (Table 2 ).

In addition, when we specifically studied the 86 patients that required ICU admission, no association was found between the presence of viremia and the development of multiorgan dysfunction syndrome prior to admission and during the first 24 h at the ICU (S2 Table) . SARS-CoV-2 viremia may enhance lung damage, leading to the need of ICU admission, while leaving other organs unaffected. Accordingly this parameter is not a good candidate biomarker to predict multiorgan dysfunction.

suggested that viremia can be associated with a higher risk of mortality, we also analyzed how both techniques predicted death during admission. TFS was more sensitive than Roche's technique but less specific either in the whole population (OR 5.8 [2.6-13.3] for Roche and 3.3 [1.4-7.4 ] for TFS), or after stratification by requirement of ICU (S2 Figure) . Therefore, we analyzed whether a threshold of viremia (as Ct) could help to better predict mortality during hospitalization. As shown in Fig. 2A www.nature.com/scientificreports/ In addition, Kaplan-Meier curves confirmed that those patients with "relevant viremia" at admission survived less than those with non-relevant detection of SARS-CoV-2 RNA (Fig. 2E ,F), being slightly higher the incidence risk ratio for viremia determined by TFS compared to Roche (IRR 4.1 [2.3-6.9] vs 2.4 [1.5-3.9] respectively).

In order to further validate the usefulness of viremia as predictor of mortality in COVID-19, we analyzed its association with clinical and laboratory parameters that have been previously associated with worse outcomes 2,7,15 . As shown in Fig. 3 , higher levels of viremia were more frequent in elderly patients (p = 0.011) and correlated with higher qSOFA (p = 0.022), CURB65 (p = 0.014) and Charlson comorbidity (p = 0.078) indexes. Furthermore, in addition to SARS-CoV-2 viremia, the prevalence of relevant SARS-CoV-2 viremia also increased with age, with significant differences between patients < 75 years and ≥ 75 years (S3 figure) .

Regarding laboratory parameters, viremia showed correlation with IL-6 serum levels and lymphocyte count (Fig. 4A ,B; p = 0.014 and p < 0.001, respectively), and a better correlation with lactate dehydrogenase serum levels ( Fig. 4C ; p < 0.001). However, lower significant association was observed with ferritin and d-dimer levels ( Fig. 4D ,E; p = 0.073 and p = 0.023, respectively).

Finally, we analyzed the hazard ratio for mortality of viremia in comparison with all these parameters. All models were adjusted by age and Charlson index, which significantly affected survival of COVID-19 patients, as well as by sex, which did not significantly affect survival. Baseline qSOFA and CURB65 showed the worst Table 2 . Variables predicting the need for Intensive Care Unit admission. COPD: chronic obstructive pulmonary disease; CI: confidence interval; OR: odds ratio; PaO 2 /FiO 2 : arterial oxygen tension-fraction of inspired oxygen ratio. 

Many efforts have been made since the first COVID-19 outbreak in China to identify poor prognosis factors in this worldwide and evolving pandemic. Several biomarkers such as low total lymphocyte count, high LDH serum levels, increased acute phase reactants (C-reactive protein, ferritin, fibrinogen, among others) or increased IL-6 serum levels have been proposed 6, 15 . Recently, detection of SARS-CoV-2 RNA in blood has been suggested as a potential severity biomarker 12, 13, [16] [17] [18] . In this regard, our results reinforce these previous data with a main contribution to the management of COVID-19: we have determined a semiquantitative threshold for SARS-CoV-2 RNA detection in serum early after admission that allows establishing RNA values ("relevant viremia") associated with higher mortality risk. Furthermore, we have shown that, technically, this finding is reproducible and, it is the most useful biomarker in the clinical setting for predicting mortality in COVID-19 patients. From a technical point of view, we were able to detect viremia with high accuracy and concordance by using two commercially available kits, from Roche and TFS, as previously described 19 . These kits had been previously approved for detecting SARS-CoV-2 in nasopharyngeal samples. Although the sensitivity of TFS technology was www.nature.com/scientificreports/ slightly better for SARS-CoV-2 RNA detection in serum, this difference disappeared when the specific Ct cut-offs for each kit were applied to define relevant viremia. These results support the notion that the viremia detection can be highly reproducible since the Roche and TFS technologies are based on different procedures for RNA extraction and retrotranscription, as well as different genes for SARS-CoV-2 detection. Furthermore, our results validate previous reports that used the Roche kit and an "in-house" kit for SARS-CoV-2 RNA detection 12, 13 . From a clinical point of view, we have shown that viremia has a high consistence as a severity biomarker in COVID-19, since it correlates with several variables that have been proposed to be associated with poor evolution in COVID-19, namely old age, comorbidity, qSOFA and CURB-65, as well as with laboratory markers such as high IL-6 or LDH serum levels and severe lymphopenia. Furthermore, multivariable Cox regression analysis identified high LDH serum levels and relevant viremia as independent and solid predictors for mortality after adjusting by age, sex, and presence of comorbidity. Neither qSOFA, CURB-65, low total lymphocyte count, nor high IL-6 serum levels maintained statistically significant association with mortality. Therefore, presence of relevant viremia was proved to be the best mortality predictor in our population since it provides a hazard ratio three times higher than that of the other significant variable, high LDH serum level. www.nature.com/scientificreports/ Certain immunological mechanisms may underlie some of these associations. First, it is tempting to suggest that a decrease in activity or number of immune cells involved in lysis of infected cells may lead to higher viral replication and viral spread in the blood. In this regard, the correlation between IL-6 levels and viremia levels could be related with the recent description of lower cytotoxic potential of NK cells and senescence of CD8+ T lymphocytes associated to high IL-6 levels, which can be restored by tocilizumab treatment 20 . Second, association between lymphopenia and viremia could be related with lymphocyte viral infection and cellular lysis by cytotoxic cells. However, lymphopenia is more likely to be related with increased cellular migration into the lungs, as we have recently described for dendritic cells 21 .

Strengths of our research include: immediacy of results during the emergency situation of the COVID-19 first wave, sufficient sample size (n = 193), fulfillment of STROBE standards for observational research, and a multifaceted view of patients including Immunology, Microbiology and many clinical assessments. However, this study has some limitations. Firstly, a single-center and retrospective design and, therefore, variability on the day of sample extraction. Nevertheless, the average time from beginning of symptoms to sample extraction (median of two days) was equal in patients with positive and negative viremia. Secondly, the moderate specificity of relevant viremia at admission to predict mortality. This finding could be associated to the variability over time of SARS-CoV-2 RNA detection in serum in COVID-19 patients 22 . Because of this variability, viremia detection at a specific time point may not properly reflect the state of viral infection, thereby influencing the assessment of severity outcomes. This could explain why previous descriptions of SARS-CoV-2 RNA detection in blood provided heterogeneous information on its value as severity biomarker 13, 14, 17 . Therefore, sequential assessment of viremia may be needed to improve its specificity to predict mortality. Last but not least, our findings are restricted to the so-called "first wave", when an overloaded health system could not cover all the needs to provide critical care in some severity ill patients. Although the results are solid, studies in new waves experienced elsewhere are needed to validate their utility throughout the pandemic.

In summary, the study presented here has established the usefulness of SARS-CoV-2 RNA detection in blood in the initial assessment of patients admitted for COVID-19 due to its capability to predict mortality. This assessment would be easily implemented since it is reproducible, regardless of the commercially available kit used for SARS-CoV-2 RNA detection. Accordingly, information from tests widely used for diagnosis could be readily used for prognosis evaluation. However, the need for quantitative standardization of relevant viremia and evaluation of the meaning of persistent Viremia must be addressed in further longitudinal studies.

Study design, population and data collection. This is a retrospective observational study of patients admitted to Hospital Universitario La Princesa (HUP) during the early weeks of the first wave of COVID-19 outbreak in Spain (Flow chart in S4 Figure) .

Study inclusion criteria were: (a) patients with confirmed detection of SARS-CoV-2 RNA in nasopharyngeal and throat swabs (NPTS), and (b) availability of serum samples at the Microbiology Department for additional measurement of SARS-CoV-2 RNA in blood. Regarding the last criterion, on average, serum samples were obtained at a median of two days from admission (interquartile range [IQR] 1 to 3) which nearly corresponded to one week after the beginning of symptoms (median: 8 days, IQR: 6 to 11).

Clinical, laboratory and therapeutic data were collected from electronic clinical records and included in an anonymized database as previously described 6 . Baseline clinical data refer to those obtained at admission day and baseline laboratory data refer to one to three days from admission date. SARS-CoV-2 RNA detection. Nasopharyngeal and throat swab samples were obtained and real-time reverse-transcription polymerase chain reaction (rRT-PCR) was performed with LightCycler Multiplex Virus Master (Roche Diagnostics, USA) using the LightMix Modular SARS and Wuhan CoV E-gene primers (Roche Diagnostics, USA), targeting the e gene as a first-line screening, followed by confirmatory testing with TaqPath COVID-19 CE-IVD Kit RT-PCR (Applied Biosystems, USA) which detects three specific SARS-CoV-2 genomic regions: orf-1ab, s, and n genes. Both procedures were performed according to manufacturers' directions on a Quant Studio-5 Real-Time PCR System (Applied Biosystems, USA) and amplification curves were analyzed with QuantStudio Design and Analysis software (Applied Biosystems, USA), for their interpretation by a clinical microbiologist.

To evaluate Viremia, we used 400 µL of surplus sera from routine HIV and hepatitis serology assessment that are usually frozen at − 20 °C for internal quality controls. Serum samples were treated previously for virus inactivation and then tested with two rRT-PCR methods: cobas SARS-COV-2 test (Roche Diagnostics, USA), a qualitative assay for detection of SARS-CoV-2 RNA, and TaqPath COVID-19 CE-IVD RT-PCR Kit (Thermo Fisher Scientific [TFS], USA), a multiplex RT-PCR assay for qualitative detection of SARS-CoV-2 nucleic acids, as previously described 19 . The number of amplification cycles needed for the fluorescence signal to cross the threshold (Ct) was recorded briefly:

(a) Roche test detects a fragment of the orf-1ab region, specific of SARS-COV-2; and a conserved region of e gene, a structural envelope gene, for pan-sarbecovirus detection. Test was performed by cobas ® 6800 System (Roche Diagnostics, USA); an automatic platform for nucleic acid extraction and RT-PCR amplification and detection. Serum samples were processed according to manufacturer's indications, following the same protocol used for SARS-CoV-2 detection in respiratory samples. Results were analyzed and interpreted automatically by the cobas 6800/8800 Software version 1.02.12.1002. (b) TFS test detects three specific SARS-CoV-2 genomic regions: orf-1ab, s, and n genes. This technique requires a previous nucleic acid extraction from the sample, which was performed by the automatic eMAG Nucleic IL-6 serum level measurement. IL-6 serum levels were quantified in duplicate with the Human IL-6

Quantikine high sensitivity enzyme-immune assay from R&D Systems Europe Ltd. (Abingdon, UK), as described previously 6 . Variables. We used two different variables to evaluate viremia: (a) dichotomic variable: viremia was considered positive when at least one of the genes studied was positive according to the output of the two systems used; and (b) quantitative variable: when more than one gene target was detected by one test, the mean Ct value of amplified genes was calculated. There was a high consistency among the results of the three genes analyzed with TFS and a slightly lower one for the two genes analyzed in the Roche system 19 . Since none of the two systems (Roche and TFS) provided positive results with Ct > 40, by consensus decision, we assigned Ct = 42 to those samples reported as negative (for all the genes) by the system. Baseline IL-6 levels were considered high if > 30 pg/ml, according to their sensitivity and specificity to predict severity determined in a previous study 6 . In addition, in order to be able to compare different biomarkers, other continuous variables previously described as COVID-19 severity biomarkers were also transformed into dichotomic variables considering as cut-off point their median values in our population, namely: total lymphocyte count was considered low when < 700 cells/mm 3 , lactate dehydrogenase (LDH) serum level was considered high when > 400 U/L, qSOFA and CURB65 were considered high if > 1. Patients were considered elderly if age > 70 years.

Multiorgan dysfunction syndrome was considered when at least two organs reached a score > 1 in SOFA scale 23 . Multiorgan failure was considered when at least two organs reached a score > 3 in SOFA scale 24 .

To analyze whether viremia could predict disease severity, two main outcomes were considered: need for ICU admission and all-cause in-hospital mortality. Only 14 patients out of 89 admitted to ICU did not require invasive mechanical ventilation.

Statistical analysis. Statistical analyses were performed using Stata 14 for Windows (Stata Corp LP, College Station, TX, USA). Quantitative variables following a non-normal distribution were represented as median and IQR, and the Mann Whitney test was used to assess significant differences. Variables with a normal distribution were described by mean ± standard deviation (SD) and differences between groups were assessed with Student's t-test. Qualitative variables were described as counts and proportions and Chi square or Fisher's exact test was used for comparisons. Correlation between quantitative variables was analyzed using the Pearson correlation test. To estimate the 95% confidence interval (CI) of correlation coefficients we used the ci2 command of Stata. To evaluate the agreement between viremia assessed by Roche and TFS we estimated the intraclass correlation with the icc command of R.

To determine the variables associated with the need for ICU admission, we performed a multivariable logistic regression analysis that was first modeled by adding all the variables with a p-value lower than 0.15 to the bivariable analysis, namely low lymphocyte count, d-dimer, high LDH, low PaO 2 /FiO 2 (< 250), COPD, high qSOFA, high CURB65, hypertension, C-reactive protein, and high IL-6 level. The final model was reached through backward stepwise removal of variables with p-value higher than 0.15 and using Wald tests to demonstrate that each model was better than its previous iteration. Once the final model was obtained, the dichotomic variables viremia (both Roche and TFS) were forced into the model in order to determine whether they were able to predict the need for ICU admission.

Odds ratio (OR) for mortality according to the presence of viremia was estimated for both systems with the cs command of Stata. Since differences between the two techniques were detected in the sensitivity to detect viremia and the capability of predicting mortality, receiver operating characteristic (ROC) analyses were performed using the roctab command in order to estimate the best cut-off point for each system. Cut-off values for relevant viremia were selected based on the best trade-off values between sensitivity, specificity and the percentage of patients correctly classified.

Survival time was analyzed by Kaplan-Meier method with the sts command of Stata. Date of admission was considered the date of entry, and for exit date we considered the date of death. For those patients without this event, the last revision of the database (electronic chart or telephone call) on May 21st was used to censor their follow-up. Differences in time to death between different variables were analyzed by log-rank test.

To compare the predictive capability of baseline viremia with that of other baseline parameters (qSOFA, CURB65, total lymphocyte count, LDH and IL-6 serum levels) described in previous publications 12, 13, 25 we fitted different Cox regression models. In the first model after adjustment by age, sex and Charlson comorbidity index, the hazard ratio (HR) for all other variables including relevant viremia by TFS or Roche was estimated. Since qSOFA and CURB65 did not reach a p-value < 0.15, they were excluded from the analysis in the subsequent models. Model 2 was adjusted by the same variables included in model 1 and low lymphocyte count, the hazard ratio for the remaining variables was then estimated. Model 3 and 4 were developed as model 2 but substituting low lymphocyte count by high IL-6 and high LDH, respectively. Madrid, (register number 4070) and it was carried out following the ethical principles established in the Declaration of Helsinki. Only oral consent was required as proposed by AEMPS (Agencia Española de Medicamentos y Productos Sanitarios, The Spanish Agency for Medicines and Medical Devices) due to the COVID-19 emergency 26 . All included patients (or their representatives) were informed about the study and gave an oral informed consent (registered in the electronic clinical chart). Patients under 18 years old were not included. This article was written following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines taking into consideration the difficulties to obtain all needed information in the setting of the COVID-19 pandemic (Appendix).

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region

Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis

Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients

IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study

Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19

Transmission of SARS-CoV-2: A review of viral, host, and environmental factors

Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19

Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019

SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: A retrospective cohort study

Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value

Risk factors for SARS-CoV-2 detection in blood of critically ill patients

The role of biomarkers in diagnosis of COVID-19-A systematic review

High frequency of SARS-CoV-2 RNAemia and association with severe disease

SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19

Relationship between serum SARS-CoV-2 nucleic acid (RNAemia) and organ damage in COVID-19 patients: A cohort study

Evaluation of two RT-PCR techniques for SARS-CoV-2 RNA detection in serum for microbiological diagnosis

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes

Detection and isolation of SARS-CoV-2 in serum, urine, and stool specimens of COVID-19 patients from the Republic of Korea

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on sepsis-related problems of the European Society of Intensive Care Medicine

Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on 'sepsis-related problems' of the European Society of Intensive Care Medicine

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

The Spanish Agency for Medicine and Health Products

Treatments available for the management of respiratory infection by SARS-CoV-2 [Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2

conceived this study

drafted the work and substantively revised it. All authors reviewed the manuscript. Funding This study was funded with grants: Fondos Supera COVID19 by Banco Santander and CRUE to CS

Spanish MINECO and Instituto de Salud Carlos III and co-funded by The European Regional Development Fund (ERDF) A way to make Europe; and co-financed by the Community of Madrid through the Covid 2019 Aid. The work of ER-V has been funded by a Rio-Hortega grant CM19/00149 from the Ministerio de Economia y Competitividad (Instituto de Salud Carlos III) and cofunded by The European Regional Development Fund (ERDF) A way to make Europe. The work of SCR-G has been funded by Fundacion Espanola de Reumatologia

in the collection, analysis, and interpretation of data

Special thanks to our patients and relatives for agreeing with the use of pseudonymized clinical data and surpluses of clinical samples to perform this study, and PhD Manuel Gomez Gutierrez for his excellent editing assistance.The authors of this manuscript have the following competing interests: SCR-G reports grants from Spanish Rheumatology Foundation, during the conduct of the study; nonfinancial support from Roche, Lilly, Pfizer, and Abbvie; personal fees and nonfinancial support from Novartis, Sanofi, and MSD and from UCB-Pharma, outside the submitted work. JA reports grants and personal fees from GlaxoSmithKline and Boehringer Ingelheim; grants from Linde Healthcare; and grants, personal fees, and nonfinancial support from Roche and from Chiesi, outside the submitted work. DAR-S reports personal fees from MSD, outside the submitted work. RdC reports personal fees from MSD, ASTELLAS, Clinigen, Janssen, Roche, and IQONE Health Care outside the submitted work. RG-V reports grants, personal fees, and nonfinancial support from Abbvie, BMS, Lilly, Novartis, Sanofi, Sandoz, and MSD; personal fees from Biogen and Celltrion and from Mylan, outside the submitted work; personal fees and nonfinancial support from Pfizer; grants from Roche; and grants and personal fees from Janssen. CSF reports personal fees from Bayer, BMS, Daichi Sankyo, MSD, and Pfizer, outside the submitted work. CM-C reports competitive grants from ISCIII during the conduct of the study. IG-A reports grants from Instituto de Salud Carlos III, during the course of the study; Personal fees from Lilly and Sanofi; personal fees and nonfinancial support from BMS and Abbvie; research support, personal fees, and nonfinancial support from Roche Laboratories; and nonfinancial support from MSD, Pfizer, and Novartis, not related to the submitted work. The rest of the authors declare that they have no relevant competing interests.